The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
 
Julia Katharina Schwarze
Travel, Accommodations, Expenses - MSD
 
Valerie Vandersleyen
No Relationships to Disclose
 
Gil Awada
Travel, Accommodations, Expenses - MSD
 
Yanina Jansen
No Relationships to Disclose
 
Teofila Seremet
Employment - GlaxoSmithKline (I); Janssen (I)
Honoraria - Janssen; Novartis
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Janssen; LEO Pharma; MSD Oncology; Novartis
 
Bart Neyns
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Etherna; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Sanofi
Speakers' Bureau - Novartis
Research Funding - Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche